Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1.000 | 0.080 | 9 | 5003338 | intron variant | G/A;C | snv |
|
Neoplasms; Male Urogenital Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||||
|
1.000 | 0.080 | 9 | 5005034 | intron variant | A/T | snv | 0.26 |
|
Neoplasms; Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||||
|
0.882 | 0.080 | 9 | 5010192 | intron variant | G/A | snv | 0.62 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.882 | 0.080 | 9 | 5010192 | intron variant | G/A | snv | 0.62 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.882 | 0.080 | 9 | 5010192 | intron variant | G/A | snv | 0.62 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.925 | 0.080 | 9 | 5015732 | intron variant | C/A | snv | 0.39 |
|
Neoplasms; Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
0.925 | 0.080 | 9 | 5015732 | intron variant | C/A | snv | 0.39 |
|
Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
1.000 | 0.040 | 9 | 5022025 | missense variant | G/T | snv | 5.2E-05 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||
|
9 | 5028921 | intron variant | C/G | snv | 0.23 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||||
|
9 | 5038597 | intron variant | TTTT/-;T;TT;TTT;TTTTT;TTTTTT;TTTTTTT | delins |
|
0.700 | 1.000 | 1 | 2016 | 2016 | |||||||||||
|
0.882 | 0.080 | 9 | 5044432 | missense variant | G/A;C | snv | 1.8E-03; 4.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.882 | 0.080 | 9 | 5044432 | missense variant | G/A;C | snv | 1.8E-03; 4.0E-06 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||||
|
0.882 | 0.080 | 9 | 5044432 | missense variant | G/A;C | snv | 1.8E-03; 4.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
9 | 5050807 | missense variant | C/T | snv | 4.0E-06 |
|
Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||||||
|
1.000 | 0.040 | 9 | 5054778 | missense variant | G/A | snv | 7.0E-06 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2010 | 2010 | |||||||
|
1.000 | 0.040 | 9 | 5055750 | stop gained | C/A;G;T | snv | 4.0E-06; 1.6E-05 |
|
Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.882 | 0.080 | 9 | 5057284 | intron variant | T/A | snv | 0.33 |
|
Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
0.882 | 0.080 | 9 | 5057284 | intron variant | T/A | snv | 0.33 |
|
Neoplasms; Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
0.882 | 0.080 | 9 | 5057284 | intron variant | T/A | snv | 0.33 |
|
Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
1.000 | 0.080 | 9 | 5059440 | intron variant | C/T | snv | 0.64 |
|
Neoplasms; Male Urogenital Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.925 | 0.080 | 9 | 5063296 | intron variant | G/T | snv | 0.34 |
|
Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2015 | 2015 | |||||||
|
0.925 | 0.080 | 9 | 5063296 | intron variant | G/T | snv | 0.34 |
|
Neoplasms; Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.925 | 0.080 | 9 | 5063296 | intron variant | G/T | snv | 0.34 |
|
Neoplasms; Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
9 | 5064193 | intron variant | T/C | snv | 0.25 |
|
Immune System Diseases | 0.700 | 1.000 | 1 | 2017 | 2017 | |||||||||
|
1.000 | 9 | 5064922 | missense variant | G/A;C;T | snv | 1.7E-05; 1.7E-05; 4.2E-06 |
|
0.010 | 1.000 | 1 | 2015 | 2015 |